The Malaysian Reserve

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term ...

Johnson & Johnson: TREMFYA (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...
Le Lézard

CyanoCapture and Persist AI Announce Strategic Collaboration to Build World's First Robotic GMP Facility for Oral Protein and Peptide Drugs

CyanoCapture, the innovator in cyanobacteriabased oral drug delivery, and Persist AI, the leader in AI-driven robotic pharmaceutical formulation, today announced a strategic collaboration to jointly ...
Le Lézard

GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership

GelMEDIX, Inc., a biotechnology company developing regenerative therapies to restore vision, announced today the completion of a $13 million seed financing led by Safar Partners, with participation ...

Johnson & Johnson Strengthens Oncology Portfolio with Key Developments

Johnson & Johnson is making significant strides in the pharmaceutical landscape, with two major announcements reinforcing its commitment to oncology. These operational advancements provide fundamental ...
pharmaphorum

J&J adds to IL-23 options in Crohn's after FDA approval

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...
Hosted on MSN

FDA Approves Tremfya for Active Crohn Disease in Adults

MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is ...
pharmaphorum

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.
National Law Review

China on the Move: Key Takeaways from the 2025 NRDL Negotiations and Adjustment

China’s role in the global pharmaceutical innovation market is undergoing a substantial shift. As of 2025, China’s share of ...
The Guardian

‘People are turning themselves into lab rats’: the injectable peptides craze sweeping the US

Though lab-made peptides are touted as a cure-all, they are not FDA-regulated and pose serious risks, experts warn Here’s a new trend that sounds unwise: buying unregulated substances from dealers in ...
Healthline

Bladder Botox for Urinary Incontinence and OAB

Botox is used to treat overactive bladder (OAB) in adults. It’s also approved to treat urinary incontinence caused by certain neurological conditions in adults and children ages 5 years and older. The ...
Healthline

Methotrexate Injection Side Effects and Tips for Managing Them

Methotrexate injection, a treatment for certain autoimmune diseases and cancers, can lead to various side effects. These range from common, mild reactions such as headache and nausea to serious, ...